PRESS RELEASE : SHOP APOTHEKE EUROPE continues its fast growth: Q4 sales up 38%, full year 2020 growth 38.1%.

 
 DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Development of 
Sales/Preliminary Results 
SHOP APOTHEKE EUROPE continues its fast growth: Q4 sales up 38%, full year 
2020 growth 38.1%. 
 
2021-01-11 / 07:00 
The issuer is solely responsible for the content of this announcement. 
 
_NOT FOR DIRECT OR INDIRECT PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO 
THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA AND JAPAN OR ANY 
JURISDICTION IN WHICH OFFERS OR SALES OF THE SECURITIES WOULD BE PROHIBITED 
BY APPLICABLE LAW._ 
 
*SHOP APOTHEKE EUROPE continues its fast growth: Q4 sales up 38%, full year 
2020 growth 38.1%. * 
 
? Preliminary sales growth of 38.0% to EUR 264.8 million in Q4 and of 
38.1% to EUR 968.2 million for the full year. 
 
? Sales for the DACH Segment +33.7% and for the International Segment 
+68.2% in Q4; +32.5% and 78.3%, respectively, for the full year. 
 
? Number of active customers increased to 6.3 million. Up 0.4 million in 
Q4 and up 1.6 million during 2020. 
 
? Growth pace continues with a good start into 2021 
 
Venlo, 11 January 2021. SHOP APOTHEKE EUROPE N.V. exceeded its ambitious 
growth targets for the 2020 financial year (balance sheet date: Dec. 31), 
according to preliminary unaudited calculations: With an increase in group 
sales of 38.1% to EUR 968.2 million for 2020, growth was at the high end of 
the latest guidance of at least 35%, which had been raised three times 
throughout the year. For Q4, sales were EUR 264.8 million, 38.0% growth 
compared to the corresponding period 2019. SHOP APOTHEKE EUROPE gained 0.4 
million active customers in Q4 and 1.6 million during the full year, 
reaching 6.3 million active customers at the end of 2020. 
 
Stefan Feltens, CEO of SHOP APOTHEKE EUROPE: "2020 was a challenging year 
for us, but also an outstanding one. Thanks to the smart thinking and 
dedicated work of our employees, we were able to manage the huge increase in 
order volumes while at the same time continuing to push ahead with a broad 
range of strategic projects. All in all, we have made significant progress 
in transforming SHOP APOTHEKE EUROPE from an online pharmacy retailer into a 
customer-centric e-pharmacy platform, which we have further advanced with 
the recent acquisition of SMARTPATIENT." 
 
In the DACH Segment (Germany, Austria, Switzerland), SHOP APOTHEKE EUROPE 
recorded 33.7% growth in Q4, resulting in sales of EUR 263.9 million. In the 
full year 2020, sales grew by 32.5% to EUR 815.5 million. In the 
International Segment (France, Belgium, Italy and the Netherlands), SHOP 
APOTHEKE EUROPE increased its sales by 68.2% to EUR 41.0 million in Q4 and 
by 78.3% to EUR 152.6 million in the full year. 
 
The sale of prescription drugs (Rx) increased by 17.6 % year-on-year, from 
EUR 186.5 million in 2019 to EUR 219.3 million in 2020. 
 
CFO Jasper Eenhorst comments: "We were able to raise our sales growth 
guidance three times last year because we seized the opportunities we saw 
and were quick to make the right decisions. This took us close to the 
billion-euro mark in sales in 2020. With the ongoing move to our new 
logistics centre and our fast-growing base of active, happy, customers we 
are also well positioned for continued growth in 2021." 
 
All published figures are preliminary and unaudited. SHOP APOTHEKE EUROPE 
will publish the complete annual report for the 2020 financial year on 3 
March 2021. 
 
*ABOUT SHOP APOTHEKE EUROPE.* 
 
SHOP APOTHEKE EUROPE is one of the leading and fastest-growing online 
pharmacies in Continental Europe. With the acquisition of Europa Apotheek 
Venlo in November 2017, SHOP APOTHEKE EUROPE significantly extended its 
European market leadership. The product range for the whole family in the 
areas of OTC, beauty and personal care products as well as prescription 
drugs is supplemented by high quality natural food and health products, low 
carb products and sports nutrition following the acquisition of nu3 GmbH in 
July 2018. 
 
SHOP APOTHEKE EUROPE operates online pharmacies in Germany, Austria, France, 
Belgium, Italy, the Netherlands and Switzerland at this moment. SHOP 
APOTHEKE EUROPE delivers a broad range of more than 100,000 original 
products to 6.3 million active customers (31 December 2020) fast and at 
attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive 
pharmaceutical consulting services. 
 
SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the 
Frankfurt Stock Exchange (Prime Standard) since 13 October 2016 and has 
moved up to the MDAX index on 21 September 2020. 
 
*PRESS CONTACTS.* 
Trade and popular media: 
Sven Schirmer 
Tel: [phone] 
Email: [e-mail] 
 
Financial media: 
Bettina Fries 
Tel: [phone] 
Email: [e-mail] 
 
Investor relations: 
Carmen Herkenrath 
Tel.: [phone] 
Email: [e-mail] 
 
Thomas Schnorrenberg 
Mobile: [phone] 
Email: [e-mail] 
 
*DISCLAIMER.* 
 
This publication constitutes an advertisement. This announcement does not 
constitute an offer for sale or a solicitation of an offer to purchase 
securities of SHOP APOTHEKE EUROPE N.V. in any jurisdiction. It does not 
constitute a securities prospectus. A public offer of securities of SHOP 
APOTHEKE EUROPE N.V. is not taking place. 
 
Statements contained herein could constitute so-called 'forward-looking 
statements'. Forward-looking statements can be recognized by words such as 
'might,' 'will,' 'should,' 'plans,' 'anticipates,' 'anticipates,' 
'estimates,' 'believes,' 'intends,' 'aims,' 'aim' or their negative form or 
corresponding modifications and comparable terms. 
 
Forward-looking statements are based on current expectations and involve a 
number of known and unknown risks, uncertainties and other factors that 
could cause the actual results, levels of utilization, developments and 
achievements of the group or industry in which it operates to be materially 
different than those contained herein or implied. There should be no undue 
reliance on forward-looking statements. The group will not update or revise 
any forward-looking statements contained herein, whether as a result of new 
information, future events or otherwise. 
 
2021-01-11 Dissemination of a Corporate News, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:    English 
Company:     SHOP APOTHEKE EUROPE N.V. 
             Dirk Hartogweg 14 
             5928 LV Venlo 
             Netherlands 
Phone:       0800 - 200 800 300 
Fax:         0800 - 90 70 90 20 
E-mail:      [e-mail] 
Internet:    www.shop-apotheke-europe.com 
ISIN:        NL0012044747, DE000A19Y072 
WKN:         A2AR94, A19Y07 
Indices:     MDAX 
Listed:      Regulated Market in Frankfurt (Prime Standard); Regulated 
             Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, 
             Munich, Stuttgart, Tradegate Exchange 
EQS News ID: 1159557 
 
End of News DGAP News Service 
 
1159557 2021-01-11 
 
 

(END) Dow Jones Newswires

January 11, 2021 01:00 ET (06:00 GMT)